The Peptide Craze: Biohacking and Human Guinea Pigs
On February 27, 2026, Robert F. Kennedy Jr. appeared on Joe Rogan’s podcast and announced that the FDA is preparing to move approximately 14 experimental peptide compounds off its restricted list and back into the hands of compounding pharmacies. He called himself a “big fan” of peptides. He said he expected the announcement “within a couple of weeks.”
One industry executive responded with what he called a prediction: “We’re about to unleash one of the biggest medical experiments in the history of America onto Americans as the test subjects.” He meant it as a good thing.
In response, first let me tell you about a patient of mine. Two weeks before I wrote this, a 40-year-old man came into my clinic in acute distress. He was intelligent, fit, and successful—and he was terrified. His throat was swelling. Hives covered his body. He was struggling to breathe. And … he had been injecting a peptide “stack” he’d ordered online. He’d been at it for exactly two weeks.
That timing is not a coincidence. Two weeks is how long it takes for our immune systems to mount a full IgE-mediated allergic response to a new foreign substance—the same mechanism behind severe penicillin reactions. With a slightly higher dose, or a slightly longer drive to my clinic, he could have gone into full anaphylaxis. He responded quickly to epinephrine and antihistamines. He will be fine. But his immune system now has a permanent record of that peptide as a lethal enemy. Any future exposure risks a faster, more severe reaction.
This is the experiment that is about to be released on the American public.
A New Label on Old Snake Oil
Quackery has long been handy with new names. “Remedies,” “tonics,” “panaceas,” and “snake oil” gave way to “complementary and alternative medicine,” which gave way to “integrative” and “functional” medicine. Today’s label is “biohacking”—and its latest product line is peptides.
To be clear: some self-experimentation is entirely reasonable. Adjusting your diet, sleep schedule, or exercise routine can have rapid results and manageable risks. That is not what I am cautioning about. I am writing about people who order vials of white powder from overseas websites, mix them with water in their kitchens, and inject themselves based on advice from social media influencers and, now, the Secretary of Health and Human Services.
This is the actual evidence base: rodent studies, discontinued trials, and anecdotes from podcast guests with financial stakes in the outcome.
If you spend any time in online “wellness” spaces, you have encountered the pitch. Coaches, longevity clinics, and podcasters hawking discount codes are aggressively marketing injectable grey-market chemicals that promise to “optimize your metabolic pathways,” “boost your immune system,” “detoxify your cellular matrix,” and “address the root cause of aging.” They claim these compounds will dramatically increase muscle mass, melt body fat, skyrocket libido, erase wrinkles, and heal injuries without the inconvenience of waiting for evidence.
As I tell my patients: if a drug could genuinely do any of that, we would all know about it. It would be very hard to hide. You would not be buying it through an internet loophole labeled “not for human consumption.” Nor would there be proclamations about what “they” don’t want you to know about this new remedy.
What Peptides Actually Are
Peptides are real, biologically important, and increasingly valuable. They are short chains of amino acids—smaller versions of proteins—that often function as chemical messengers in the body. Insulin is a peptide. More than 40 peptide hormones are known in humans, governing everything from blood pressure to appetite to milk production. The body’s own peptides act quickly: released, delivered to a specific receptor, then broken down by enzymes within minutes.
Medicine has successfully harnessed this biology. There are now more than 100 FDA-approved peptide drugs on the market. The GLP-1 medications—Ozempic, Wegovy, and their weight-loss relatives—have genuinely revolutionized the treatment of diabetes and obesity. Peptide pharmacology is good, productive science, and anyone who tells you the FDA is categorically hostile to peptides is simply wrong.
The compounds being sold by anti-aging clinics and wellness websites are a different kettle of goo. These are unapproved, experimental, synthetic molecules manufactured in a regulatory and industrial grey zone. They are sold with legally evasive disclaimers—”for research purposes only,” “not for human consumption”—while being marketed with explicit instructions for human injection. Many are synthesized in foreign facilities and imported for sale online. The FDA does not approve them. Independent quality testing is essentially nonexistent.
The Appeal-to-Nature Fallacy, Wearing a Lab Coat
Peptide sellers claim their products are “gentle” and “natural” because the body already produces similar molecules. This argument collapses on inspection.
Because our natural peptides are removed by enzymes within minutes, lab-made versions must be chemically engineered to survive much longer in the bloodstream. This is why an Ozempic injection can last a week. The molecule is altered—designed to evade the very mechanisms that keep natural signaling tight, targeted, and controlled. Calling a chemically tweaked, enzyme-resistant synthetic compound ordered from an overseas supplier a “natural holistic remedy” is a remarkable feat of cognitive dissonance.
The natural precedent proves nothing about safety or efficacy at supraphysiological doses. The dose, the duration, the delivery route, and the molecular structure all matter enormously. This is not ideology. It is pharmacology.
The Wolverine Stack and Tooth Fairy Science
One popular combination—BPC-157 and TB-500—is marketed as the “Wolverine Stack,” named after the X-Men character’s mutant regenerative ability. Sellers claim it heals torn ligaments, repairs damaged tissue, and accelerates recovery from virtually any injury.
BPC-157 is a synthetic analog of a compound found in human stomach juice. In rats and cell cultures, it has shown interesting tissue-regeneration effects. There is no robust human clinical trial evidence that BPC-157 accelerates injury recovery, reduces inflammation, or supports gut health. A Phase I trial conducted in 2015 on 42 volunteers was discontinued and no results were ever published. The only human data in the published literature consist of a retrospective analysis of 12 patients and a pilot study with two participants. Based on this, influencers and longevity clinics sell it as a proven cure-all. At a MAHA (Make America Healthy Again) summit in Washington last November, a panelist told the audience his grandmother was taking it and that “it’s just one example of these products that can change people’s lives.” The audience clapped and whooped.
Then there are the peptides that are alleged to pump up growth hormone—CJC-1295 and Ipamorelin—heavily marketed to men hoping to reclaim muscle and youth without effort. What rat data actually showed for Ipamorelin was increased body weight and increased fat. Its only significant human clinical trial, investigating bowel function after surgery, found it no more effective than placebo. As for CJC-1295: clinical trials investigating it as a treatment for HIV patients were permanently halted after a participant died of a heart attack.
This is the actual evidence base: rodent studies, discontinued trials, and anecdotes from podcast guests with financial stakes in the outcome. The plural of anecdote is not data.
Downplaying Risks
The FDA’s 2023 decision to move many of these compounds to its Category 2 restricted list was not arbitrary bureaucratic overreach. It was grounded in specific, documented biology.
BPC-157 promotes angiogenesis—the formation of new blood vessels. This sounds appealing for tendon repair. It is considerably less appealing when you consider that angiogenesis is also precisely what early-stage, undetected cancers need to grow and spread. (Oncologists have long sought anti-angiogenesis drugs to attenuate the growth of blood vessels to cancerous tumors.) A person injecting unapproved angiogenic compounds has no way of knowing whether they are healing a joint or feeding a tumor. Growth hormone secretagogues carry documented risks of acromegaly—the pathological and irreversible enlargement of bones and organs from excess growth hormone exposure.
Then there is immunogenicity, the actual problem illustrated by my patient. Because synthetic peptides are engineered to persist in the bloodstream far longer than natural ones, the immune system frequently recognizes them as foreign invaders. It builds antibodies. In the best case, those antibodies simply neutralize the drug, rendering it ineffective. In worse cases, they trigger escalating allergic responses. In the worst cases, they cause anaphylaxis.
There is no quality control. There is no chain of custody. The buyer has no reliable way to know what is actually in the vial.
Then there is contamination. Grey-market peptide vials from unregulated sources often contain chemical residues from synthesis, heavy metals, bacterial contamination, or simply the wrong compound entirely. There is no quality control. There is no chain of custody. The buyer has no reliable way to know what is actually in the vial.
We are already seeing the collateral damage. Bad injections have produced hospitalizations for muscle paralysis, scarring, and sepsis. In Las Vegas, two women were hospitalized with swollen tongues, respiratory distress, and elevated heart rates—classic anaphylaxis—following peptide injections at an anti-aging festival. Medical journals have reported cases of necrotizing pancreatitis directly linked to unregulated peptide use.
The MAHA Paradox
Here is where the story becomes increasingly interesting, and particularly strange.
Kennedy is not entirely wrong about one thing. When the FDA moved these compounds to Category 2 in 2023, it did not eliminate demand. It drove patients toward Chinese suppliers and grey-market “research chemical” vendors with no oversight whatsoever. Kennedy acknowledged this directly, stating that the restrictions “created the gray market.” There is a narrow, genuine point buried here: regulated compounding pharmacy access, with physician oversight and USP-compliant quality controls, is meaningfully safer than a vial of white powder ordered from an overseas website.
But reclassification from Category 2 to Category 1 does not mean FDA approval. It does not mean these compounds are safe or effective. It means licensed compounding pharmacies would be permitted to prepare them under physician prescription for individual patients. The evidence base does not change. The angiogenesis risk does not change. The immunogenicity risk does not change. The absence of human clinical trial data does not change. What changes is the supply chain—and while that matters for contamination risk, it does nothing about the fundamental problem that we do not know what these compounds actually do in human beings at the doses being used.
Meanwhile, the people celebrating the loudest have the most to gain financially. Brigham Buhler, the compounding pharmacy and wellness clinic owner, who has Kennedy’s ear and has been loudly predicting regulatory liberation on podcasts, owns the businesses that would compound and sell these newly accessible peptides. At the MAHA summit last November, he moderated a discussion on compounding pharmacies, and declared, “I think the future is bright with peptides.” The audience, again, clapped and cheered. The financial conflicts of interest here are not subtle.
Eric Topol, director of the Scripps Research Translational Institute, identified the deeper contradiction more sharply than I could: “These are the same people that won’t take a vaccine that’s been shown to work in millions of people.”
Read that again. The MAHA movement—which has spent years amplifying vaccine hesitancy, questioning FDA-approved treatments, and casting pharmaceutical medicine as a corrupt conspiracy—is now enthusiastically championing the mass use of unapproved synthetic compounds based on rodent studies and podcast testimonials. They claim that the FDA was corrupt and captured when it approved vaccines backed by Phase III trials enrolling tens of thousands of participants. It is apparently now a liberating force when it opens the door to peptides with two-patient pilot studies.
The standard of evidence, it turns out, is not a principle. It is a preference.
A Multi-Million Dollar Experiment
The market is already staggering. U.S. Customs data show that imports of peptide and hormone compounds reached $328 million in just the first three quarters of 2024—up from $164 million during the same period the year before. That was before a sitting cabinet secretary went on the most popular podcast in America to announce that the regulatory gates are opening.
Wellness clinics function as middlemen, lending a veneer of medical legitimacy while requiring patients to sign waivers acknowledging the substances are experimental—a maneuver that transfers liability to the patient. The proponents of “functional” medicine who accuse conventional physicians of “just pushing pills” are simultaneously instructing patients to inject unapproved synthetic compounds mixed in their own kitchens. This is not a contradiction they appear to notice.
Patients frustrated by the pace of conventional healing, or simply hoping to optimize bodies that are already healthy, are understandable targets for this marketing. But enthusiasm and financial interest are not substitutes for evidence.
Caveat Emptor
Peptide pharmacology is a burgeoning field of research. FDA-approved peptide drugs have produced genuine medical advances. The problem is not peptides. The problem is the systematic exploitation of public enthusiasm for that science to sell unproven, potentially dangerous compounds to people willing to self-inject in pursuit of a shortcut—and now, the prospect of that exploitation being scaled and legitimized by federal policy.
Here is a simple test. If a compound genuinely possessed the ability to burn fat, build muscle, regenerate tissue, and reverse aging without meaningful adverse effects, it would not need to be endorsed on a podcast. It would not need a cabinet secretary to rescue it from regulatory scrutiny. It would survive clinical trials. It would earn FDA approval. It would be prescribed by physicians and covered by insurance.
It would simply be called medicine.
The man whose throat was swelling in my clinic was not a fool. He was a careful, educated person who trusted the wrong sources. He got lucky. As the regulatory gates open and the market expands, not everyone will.